Latest Cancer News

FDA Approves First-of-its-kind Kisqali® Femara® Co-Pack For Initial Treatment Of HR+/HER2- Advanced or Metastatic Breast Cancer (05-31-2017)

The US Food and Drug Administration (FDA) has approved the Kisqali ®Femara ® Co-Pack (ribociclib tablets; letrozole tablets) for the treatment of hormone receptor-positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer in postmenopausal women 1. The Kisqali-Femara Co-Pack is the first, and only currently available, combination pack with two [...]


Imfinzi Improves Outcomes for Patients With Stage III Non Small Cell Lung Cancer (05-30-2017)

Positive results for the PACIFIC clinical trial evaluating the novel precision medicine, Imfinzi (durvalumab) as sequential treatment in patients with Stage III non-small cell lung cancer (NSCLC) who had not progressed following standard platinum-based chemotherapy concurrent with radiation therapy have been reported.1 Lung cancer remains the leading cause of cancer-related deaths [...]


Opdivo Precision Cancer Medicine Improves Outcomes in Advanced Liver Cancer (05-18-2017)

Results from the CheckMate 040 clinical trial have been recently reported and found that Opdivo (nivolumab), an immuno-oncology drug which acts by modulating the immune system, produces durable responses with long-term survival rates in patients with liver cancer, regardless of whether or not patients were infected with Hepatitis B or [...]


Skin Cancer Prevention Tips from the Skin Cancer Foundation (05-17-2017)

The development of skin cancer is certainly a risk for any individual, but particularly for those of us who spend time in the outdoors. As summer approaches it’s important to keep in mind that by taking certain steps to protect yourself from the sun, you can safely enjoy your time [...]


Half of Breast Cancer Patients Pursue Reconstructive Surgery Without Understanding of Risks (05-16-2017)

More than half of breast cancer patients (57 percent) undergoing mastectomy lack the necessary medical knowledge to make a high-quality decision about reconstructive surgery that aligns with their personal goals, suggesting a trend toward overtreatment, according to a new study conducted by researchers at The Ohio State University Comprehensive Cancer Center [...]


Avelumab Immunotherapy Approved for Bladder Cancer (05-15-2017)

Bavencio (Avelumab), a programmed cell death ligand–1 (PD L1) inhibitor, has been approved for treatment of patients with locally advanced or metastatic urothelial carcinoma whose disease progressed during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy. Discuss this article with other patients and caregivers- [...]


FDA Approval Suggests Keytruda® Combined With Chemotherapy May Become New Standard Initial Treatment for Patients With Metastatic Non-Small Cell Lung Cancer (05-11-2017)

The U.S. Food and Drug Administration (FDA) has approved Keytruda® (pembrolizumab), an anti-PD-1 precision cancer medicine, in combination with Alimta®  (pemetrexed) and carboplatin chemotherapy as first-line treatment of metastatic non-small cell lung cancer (NSCLC), irrespective of PD-L1 expression. Lung cancer remains the leading cause of cancer-related deaths worldwide. In the [...]


FDA Approves Imfinzi for Treatment of Urothelial Cancer (05-11-2017)

The US Food and Drug Administration (FDA) today granted accelerated approval to Imfinzi (durvalumab) for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or who have disease progression within 12 months of treatment with that chemotherapy. Bladder cancer [...]


First New Drug for Liver Cancer in a Decade: Stivarga (05-8-2017)

The US Food and Drug Administration (FDA) has expanded the indication for Stivarga (regorafenib) to now include treatment for patients with hepatocellular carcinoma (HCC) who have previously been treated with the drug Nexavar. Expansion of Stivarga, ‘s indication marks the first FDA-approved treatment for a liver cancer in almost a [...]


Kite Pharma Updates Results of CAR-T cell therapy in Aggressive Non-Hodgkin Lymphoma (05-4-2017)

Results from the ZUMA-1 trial of axicabtagene ciloleucel (KTE-C19) in patients with chemorefractory aggressive non-Hodgkin lymphoma (NHL) were updated recently at the American Society of Hematology Annual Meeting in San Diego, California.  Overall 76% of patients with Diffuse Large B-Cell Lymphoma (DLBCL) responded to treatment, 47% achieving a complete remissions [...]


Endometriosis Patients are at Increased Risk for Ovarian Cancer, Study Confirms (05-3-2017)

A large study based on the Nurses’ Health confirms that endometriosis is associated with increased risk of ovarian cancer.  Moreover, it further clarifies that this condition is not linked to a greater risk for endometrial cancer. Many women with endometriosis are asymptomatic and only in more severe cases are these [...]


Have a Question about Chronic Myeloid Leukemia? Join us on May 25th! (05-2-2017)

CancerConnect Presents: Ask the Expert with Dana-Farber Cancer Institute’s Dr. Luskin CancerConnect announces the opportunity to engage with leukemia expert, Marlise Luskin, MD, MSCE. On May 25th, 2017, Dr. Luskin will answer your pre-submitted questions about chronic myeloid leukemia (CML) on CancerConnect. CancerConnect is an online support community for individuals [...]


« Previous PageNext Page »